Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Revenue (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Revenue for 3 consecutive years, with $32000.0 as the latest value for Q4 2025.

  • Quarterly Revenue fell 99.75% to $32000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.5 million through Dec 2025, down 50.61% year-over-year, with the annual reading at $22.5 million for FY2025, 50.61% down from the prior year.
  • Revenue hit $32000.0 in Q4 2025 for NewAmsterdam Pharma, down from $348000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $29.1 million in Q3 2024 to a low of $32000.0 in Q4 2025.
  • Historically, Revenue has averaged $6.8 million across 3 years, with a median of $2.6 million in 2023.
  • Biggest five-year swings in Revenue: skyrocketed 1490.54% in 2024 and later crashed 99.75% in 2025.
  • Year by year, Revenue stood at $803000.0 in 2023, then surged by 1490.54% to $12.8 million in 2024, then plummeted by 99.75% to $32000.0 in 2025.
  • Business Quant data shows Revenue for NAMS at $32000.0 in Q4 2025, $348000.0 in Q3 2025, and $19.1 million in Q2 2025.